Patient characteristics
| Number of patients (n=105, %) | |||
| Aciclovir (n=87) | VZIG (n=18) | Total (n=105) | |
| Age (years) | |||
| 1<2 | 3 | 0 | 3 (2.9) |
| 2<3 | 9 | 3 | 12 (11.4) |
| 3<4 | 18 | 4 | 22 (20.9) |
| 4<5 | 18 | 1 | 19 (18.1) |
| 5<6 | 18 | 4 | 22 (20.9) |
| 6<7 | 5 | 0 | 5 (4.8) |
| 7<8 | 8 | 1 | 9 (8.6) |
| 8<9 | 4 | 2 | 6 (5.7) |
| 9<10 | 3 | 0 | 3 (2.9) |
| 10<11 | 1* | 3 | 4 (3.8) |
| Gender | |||
| Male | 60* | 9 | 69 (65.7) |
| Female | 27 | 9 | 36 (34.3) |
| Not known | 18 | ||
| Diagnosis group | |||
| Acute leukaemia | 55* | 9 | 64 (61.0) |
| CNS tumour | 5 | 3 | 8 (7.6) |
| LCH | 7 | 2 | 9 (8.6) |
| Solid tumour | 18 | 4 | 22 (21.0) |
| Other | 2 | 0 | 2 (1.9) |
| VZV serostatus at diagnosis | |||
| Positive | 3 | 0 | 3 (2.8) |
| Negative | 75* | 14 | 89 (84.8) |
| Not known | 4 | 3 | 7 (6.7) |
| Equivocal | 5 | 1 | 6 (5.7) |
| VZV serostatus at exposure | |||
| Negative | 39* | 14 | 53 (50.5) |
| Not known | 47 | 4 | 51 (48.6) |
| Equivocal | 1 | 0 | 1 (0.9) |
| Source of exposure | |||
| School/nursery | 53* | 10 | 63 (60) |
| Household | 12 | 3 | 15 (14.3) |
| Hospital/clinic | 12 | 2 | 14 (14.3) |
| Other, for example, party | 10 | 3 | 13 (12.4) |
*One patient on Valaciclovir.
CNS, central nervous system; LCH, Langerhans cell histiocytosis; VZIG, varicella zoster immunoglobulin; VZV, varicella zoster virus.